TABLE 1.
IC50 relative to control (no nucleosides) | |||
---|---|---|---|
Treatment | 50 µM uridine | 50 µM deoxyuridine | P (comparison between nucleotide treatments) |
5-Fluorouracil | 0.88 ± 0.18 | 0.91 ± 0.31 | >0.1 |
Methotrexate | 0.93 ± 0.03 | 0.86 ± 0.03 | 0.06 |
Values are means ± SDs of the normalized ratio of 2 independent experiments. IC50 curves were generated by using 0.1–1000 µM 5-fluorouracil and 0.001–0.5 µM methotrexate; viability was measured by using the MTT assay. IC50 values for each treatment were normalized to IC50 of control (no nucleoside supplementation). IC50, concentration of an inhibitor where the response is reduced by half; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide.